OncLive SOSS

Authors

Sara A. Hurvitz, MD, FACP

Latest:

T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights

Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations.

Tarita Thomas, MD, PhD, MBA

Latest:

Thomas and Lukas Highlight Updates in Brain Cancer from the 2024 ASCO Annual Meeting

Drs Thomas and Lukas discusses highlights in brain cancer research from the 2024 ASCO Annual Meeting.

Christina Poh, MD

Latest:

Dr Poh on the Preliminary Efficacy of Tafasitamab Plus Lenalidomide and Rituximab for R/R Follicular Lymphoma

Christina Poh, MD, discusses results from the phase 3 inMIND study of tafasitamab plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma.

Burak Zeybek, MD

Latest:

Dr Zeybek on the Investigation of Neoadjuvant Olaparib in Newly Diagnosed BRCA-Mutant Ovarian Cancer

Burak Zeybek, MD, discusses key results and clinical implications from the phase 1 NOW trial investigating neoadjuvant olaparib in patients with newly diagnosed, BRCA-mutant ovarian cancer.

Latest:

Surgical Intervention Provides the Foundation for Exploring Immunotherapy in Glioblastoma

Because the current standard-of-care modalities have significant limitations, there has been a great interest in pursuing immunotherapeutic strategies for glioblastoma.

Melina Elpi Marmarelis, MD

Latest:

How Biomarker Testing Could Continue to Evolve in NSCLC

Jessica Donington, MD, MSCR, Melina Elpi Marmarelis, MD, and Ibiayi Dagogo-Jack, MD, on the next steps for biomarker testing in NSCLC.

Katherine Wang, MD

Latest:

Dr Wang on the Role of Active Surveillance in Patients With Renal Masses

Katherine Wang, MD, discusses the role of active surveillance for patients with renal masses and the ongoing MUSIC-KIDNEY project in Michigan.

Shambavi Richard, MD

Latest:

Therapeutic Frontiers Expand for Patients With Relapsed/Refractory Multiple Myeloma

Various immune strategies have been developed in multiple myeloma, including immune-enhancing drugs such as immunomodulatory drugs, checkpoint inhibitors, monoclonal antibodies, and, more recently, chimeric antigen receptor T-cell therapy and bispecific antibodies for T-cell redirection.

Karin A. Skalina, MD, PhD

Latest:

Precision Cancer Care: Preserving Normal Tissue With Proton Therapy

Radiation therapy is a critical component of cancer care that is currently being used in approximately 50% of all patients with cancer.

Jacob Shreve, MD, MS

Latest:

The Medical AI Revolution

We consider artificial intelligence hype vs reality, focusing on predictive modeling to answer medical questions about diagnosis, treatment choice, etc.

Rupert Bartsch, MD

Latest:

Dr Bartsch on the TUXEDO-1 Trial of T-DXd in HER2+ Breast Cancer With Brain Metastases

Rupert Bartsch, MD, discusses findings from the final analysis of the phase 2 TUXEDO-1 trial of trastuzumab deruxtecan in patients with HER2-positive breast cancer with active brain metastases.

John Michael Kaczmar, MD

Latest:

Dr Kaczmar on the Future Utility of Cemiplimab With Fianlimab in Advanced Melanoma

John Michael Kaczmar, MD, discusses future implications for the use of fianlimab in combination with cemiplimab for the treatment of patients with advanced melanoma.

Kian-Huat Lim, MD, PhD

Latest:

Dr Lim on Multidisciplinary Approaches to Pancreatic Cancer Management

Kian-Huat Lim, MD, PhD, discusses the importance of multidisciplinary collaboration when diagnosing and treating patients with pancreatic cancer.

Aaron E. Katz, MD

Latest:

Dr Katz on a Cystoscopic Cryocatheter in Bladder Cancer

Aaron E. Katz, MD, discusses the rationale for and findings from a preclinical study evaluating the efficacy of a novel cystoscopic cryocatheter for in situ bladder cancer destruction.

Barbara Ann Karmanos Cancer Institute

Latest:

Barbara Ann Karmanos Cancer Institute and Wayne State University Name Boris C. Pasche, MD, PhD, FACP, President and Chief Executive Officer

The Barbara Ann Karmanos Cancer Institute, part of Grand Blanc-based McLaren Health Care and a National Cancer Institute-designated Comprehensive Cancer Center, in conjunction with Wayne State University, have named Boris C. Pasche, MD, PhD, FACP, President & Chief Executive Officer and Chair of the Department of Oncology at the Wayne State University School of Medicine.

Bradley D. Hunter, MD

Latest:

Asciminib and Ponatinib Sit at the Forefront of Advances in CML Management: Insights From Onyee Chan, MD; and Bradley D. Hunter, MD

Drs Chan and Hunter discuss asciminib in first-line CML, OPTIC trial data on ponatinib dosing, mutational testing, and stem cell transplant strategies.

Yi-Bin Chen, MD

Latest:

Quality of Life and Patient Reported Outcomes (PRO) in Chronic GVHD

The expert doctors discuss the impact of chronic GVHD on long-term survivors' quality of life (QoL). The panel explores the significance of patient-reported outcomes (PROs), challenges in their implementation, and the evolving role of PROs in assessing and improving QoL in chronic GVHD patients.

Kristen M. O’Dwyer, MD

Latest:

Clinical Trials and Real-World Data on Brexu-Cel

Panelists discuss how the dosing and lymphodepletion regimens of brexucabtagene autoleucel (brexu-cel), tisagenlecleucel (tisa-cel), and obecabtagene autoleucel (obe-cel) differ, with insights into obe-cel’s double infusion approach, as well as a deeper dive into the ZUMA-3 trial’s design and data updates with brexu-cel in relapsed/refractory acute lymphoblastic leukemia (R/R ALL).

Ryan Hickey, MD, New York University Langone Health

Latest:

Rapid Readouts: Personalized versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomized, multicentre, open-label phase 2 trial

Ryan Hickey, MD, presents data from the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium on results of the phase 2 DOSISPHERE-01 trial of personalized vs standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma.

Latest:

Dr Amini on High-Risk Factors Associated With Cardiac Toxicities in Lung Cancer

Arya Amini, MD, discusses cardiac toxicities associated with lung cancer.